Market Trends of China Diabetes Devices Industry
Monitoring Devices Market is growing with the highest CAGR in forecast period
Patients diagnosed with type-1 diabetes (T1D) are tasked with maintaining a healthy lifestyle, a challenge influenced by individual personality traits, social interactions, socioeconomic circumstances, and environmental factors. The integration of continuous glucose monitoring (CGM) alongside multiple daily injections (MDI) has proven effective in reducing both non-severe and severe hypoglycemia among individuals with T1 diabetes prone to such events. Remarkably, even amidst the challenging conditions imposed by the severe lockdown during the COVID-19 pandemic crisis, patients at high risk of hypoglycemia managed to control their blood sugar levels through standalone continuous glucose monitoring.
Managing viral infections in individuals with diabetes poses challenges due to variations in blood glucose (BG) levels. Real-time continuous glucose monitoring (RT-CGM) enables the monitoring of BG trends, allowing for intervention to prevent drastic fluctuations before they lead to complications. The Dexcom G4 Platinum CGM system's impressive range of up to 6.0 meters reduces the need for medical personnel to enter isolation rooms, enhancing safety protocols.
These advancements contribute to the growth of the monitoring device market in China. The increasing number of generic manufacturers in the country aligns with the growing preference among type-1 diabetes patients for cost-effective treatments, thereby supporting the expansion of the market under scrutiny.
Increasing Type -1 Diabetes Population in China
According to estimates, 1 in 10 Chinese citizens have diabetes. During the 21st Century, millions of new cases of diabetes are occurring each year. However, a precise statistic for diabetes in China is difficult to calculate because many cases remain undetected. China is believed to have surpassed India as the country with the most significant diabetes population in the world.
Diabetes is most prevalent in China's cities, where economic growth is accelerating, and traditional dietary patterns are rapidly eroding. According to China health experts, the fundamental causes of this diabetes number spike include urbanization, improving living standards, and an aging population. According to the National Health Commission, China has made steps to reduce diabetic and high blood pressure patients' medical expenses by reimbursing outpatients for more than half of their medication costs (NHC).
According to the National Metabolic Disease Clinical Research Center, more hospitals in China will establish National Metabolic Management Centers (MMC) as part of their exploration of a new model of diabetes treatment. According to the National Health Commission, China Statistics, MMCs have provided services for more than 200,000 patients over the last two years.
As a result, the diabetes care market in China is predicted to expand gradually in the coming years.
